Last reviewed · How we verify
Phase 1: Risperidone
Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.
Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar disorder (acute mania), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Phase 1: Risperidone |
|---|---|
| Sponsor | Shanghai Mental Health Center |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Risperidone antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. This dual mechanism makes it an atypical antipsychotic with a favorable side effect profile compared to first-generation agents.
Approved indications
- Schizophrenia
- Bipolar disorder (acute mania)
- Irritability associated with autism spectrum disorder
Common side effects
- Weight gain
- Sedation
- Prolactin elevation
- Extrapyramidal symptoms
- Orthostatic hypotension
- Akathisia
Key clinical trials
- Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008) (PHASE2)
- A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia (PHASE2, PHASE3)
- Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia (PHASE1)
- Adjunctive iTBS for First-Episode Schizophrenia (NA)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Risperidone for the Treatment of Huntington's Disease Involuntary Movements (PHASE2)
- Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |